Investor Overview

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

(Common)
Price	Change	% Change	Volume

Previous Close	Today's Open	Intraday High	Intraday Low

Exchange: (US Dollar)
Aug 14, 2020 6:51 PM EDT

Date	Title
07/29/20	Investor Presentation 1.4 MB
05/08/20	AtriCure CONVERGE Investor Presentation in Conjunction with HRS 2.9 MB
04/29/20	2019 Annual Report 1.9 MB
08/12/19	Acquisition of SentreHEART Overview 778.9 KB

Date	Title
08/06/20	AtriCure Announces Angie Wirick as Chief Financial Officer MASON, Ohio --(BUSINESS WIRE)--Aug. 6, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal
07/29/20	AtriCure to Participate at Upcoming Investor Conferences MASON, Ohio --(BUSINESS WIRE)--Jul. 29, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
07/28/20	AtriCure Reports Second Quarter 2020 Financial Results Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2020-- AtriCure, Inc.
07/07/20	AtriCure to Announce Second Quarter 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020 .

Date	Title
08/06/20	AtriCure Announces Angie Wirick as Chief Financial Officer MASON, Ohio --(BUSINESS WIRE)--Aug. 6, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal
07/29/20	AtriCure to Participate at Upcoming Investor Conferences MASON, Ohio --(BUSINESS WIRE)--Jul. 29, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.
07/28/20	AtriCure Reports Second Quarter 2020 Financial Results Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2020-- AtriCure, Inc.
07/07/20	AtriCure to Announce Second Quarter 2020 Financial Results MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020 .

More National News >>

Date	Title
08/13/19	AtriCure Completes Acquisition of SentreHEART MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
08/28/18	AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.
06/05/18	AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...
04/25/17	AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it

More International News >>